SheMed
SheMed is a London-based, female-founded telehealth platform offering clinician-led GLP-1 weight-management programmes tailored for UK women, combining at-home needle-free blood testing, personalised prescribing, and app-based monitoring for 100,000+ members.
- Company typePrivate
- Founded2024
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2C
- OfferingServices
What SheMed does
SheMed is a London-based, female-founded women's health technology company operating a direct-to-consumer telehealth platform for clinician-led weight management. Founded in April 2024 by sisters Olivia and Chloe Ferro, the company serves UK women aged 18-85 who meet NHS-style eligibility for weight-loss medication (BMI ≥30, or ≥27 with comorbidities), with particular emphasis on cohorts under-served by mainstream providers — women navigating perimenopause, menopause, and PMOS/PCOS. The platform combines at-home needle-free blood testing (using Tasso device technology for HbA1c, cholesterol, liver, and kidney screening), clinician-led prescribing of Wegovy, Mounjaro, and oral semaglutide, and an all-in-one mobile app for ordering, progress tracking, weekly check-ins, and clinician messaging. Pharmacy dispensing and clinical/prescribing services are delivered through partner eMed Healthcare UK, a GPhC-registered pharmacy (#9012578) and CQC-registered provider (#1-1690359844), making regulatory compliance a partnership dependency rather than an in-house capability.
SheMed runs a subscription revenue model with monthly plans starting at £59 in the first promotional month (bundling a £100 blood test, medication, clinical support, and a side-effect care package), then from £139/month rolling, plus 3/6/12-month commitment tiers with early-termination fees, and two £24.99/month supplement add-ons (GLP-1 Daily Support & Sleep; Hair, Skin & Nails). Marketing is digital-first — content/SEO, email, paid social, a £40/head referral programme, an affiliate programme tracked via Rewardful, and a Birmingham City FC sponsorship — and the entire customer journey runs through a self-serve online eligibility quiz and the SheMed app. The company scaled to 100,000+ UK members within roughly 18 months, raising a $50 million Series A in October 2025 at a $1 billion valuation (unicorn status) and setting an explicit target of 250,000 women by 2026.
The clinical differentiator is a female-specific protocol layer addressing hormonal drivers of weight gain that mainstream GLP-1 programmes ignore, supported by a 12-month real-world evidence study launched in December 2024 (results expected early 2026) examining outcomes beyond weight loss in PMOS, endometriosis, menopause, and cardiometabolic health. The Wegovy oral pill, launched in 2026 as a needle-free alternative, further broadens the addressable market. Geographic concentration is currently total — UK only — and operational scale remains a single-market bet, with all clinical, pharmacy, and distribution infrastructure routed through one regulated pharmacy partner.
SheMed firmographics
Firmographics- Name
- SheMed
- Legal name
- SheMed
- Website
- https://shemed.co.uk
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SheMed is a London-based, female-founded telehealth platform offering clinician-led GLP-1 weight-management programmes tailored for UK women, combining at-home needle-free blood testing, personalised prescribing, and app-based monitoring for 100,000+ members.
- Ownership category
- akta.pro rank
SheMed industry classification
Industry- Product category
- Women's Telehealth Weight Management
- NAICS
- Other Ambulatory Health Care Services (6219)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Prescription-Based Digital Clinics (Condition-Specific Rx Programs) (HLALAAAD)
- akta.pro secondary industry
- Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing (HLALAIAH)
Keywords
Where SheMed is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
SheMed business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Weight Loss Programme Subscription: Monthly subscription plans (rolling monthly, 3-month, 6-month, 12-month) bundling blood tests, GLP-1 medication (Wegovy/Mounjaro), clinical support, app access, and side-effect care. First month from £59, then from £139/month.
- Supplements: GPL-1 Daily Support & Sleep (£24.99/month) and Hair, Skin & Nails (£24.99/month) supplements sold as add-on subscriptions to programme members.
- Affiliate Commission: UK-based affiliates earn commission for each successful referral who completes their first order. Paid monthly via PayPal.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | First month promotional price |
| Subscription | Monthly | Rolling monthly subscription |
| Subscription | Multi-year contract | 3/6/12-month commitment plans |
| Subscription | Monthly | GPL-1 Daily Support & Sleep supplement |
| Subscription | Monthly | Hair, Skin & Nails supplement |
| Subscription | Monthly | Wegovy pill (oral semaglutide) |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels9 records
SheMed product offering
Product offeringCore offering
SheMed is a UK women's health technology company offering a clinician-led, personalised medical weight loss programme built around GLP-1 medications (Wegovy and Mounjaro injections, plus oral Wegovy pill). The service combines at-home needle-free blood testing for metabolic screening, ongoing clinician oversight, and an all-in-one mobile app for ordering, tracking, and check-ins. Membership is delivered via recurring subscription bundles that include medication, blood tests, clinical support, and side-effect care.
Product overview
SheMed is a UK-based women's health technology company offering a personalised, clinician-led medical weight loss programme built around GLP-1 medications. The core offering is the SheMed Medical Weight Loss Programme, which combines Wegovy (semaglutide) and Mounjaro (tirzepatide) in both injectable and oral (Wegovy pill) forms, supported by at-home needle-free blood testing and metabolic monitoring. Members access care through a companion mobile app providing progress tracking, weekly check-ins, and clinician support. Supplementary offerings include two branded supplements (GLP-1 Daily Support & Sleep, and Hair, Skin & Nails), an ongoing clinical study investigating women's health outcomes beyond weight loss, a referral programme (£40 per successful referral), and an affiliate programme for UK-based promoters tracked via Rewardful. The pharmacy and prescribing services are delivered in partnership with eMed Healthcare UK (GPhC- and CQC-registered).
Differentiator
Problem solved
Functional benefit
Products and services
- SheMed Medical Weight Loss Programme Clinician-led, personalised medical weight loss programme for UK women using GLP-1 medications (Wegovy and Mounjaro injections or oral Wegovy pill), supported by at-home blood testing, metabolic monitoring, and an all-in-one mobile app for ordering, tracking, and clinician check-ins. Delivered as a monthly or multi-month subscription.
- Wegovy Pill (Oral Semaglutide) MHRA-approved daily oral weight-loss tablet containing semaglutide, offered as a needle-free alternative to injectable GLP-1 therapy. Available privately from SheMed from £69/month including clinical support, blood test, and side-effect care.
- GLP-1 Injection Programme (Wegovy and Mounjaro) Weekly injectable GLP-1 medications (Wegovy and Mounjaro) prescribed as part of a personalised weight-loss plan, including dose titration, metabolic monitoring, and the ability to switch between medications or delivery methods.
- At-Home Needle-Free Blood Test Needle-free at-home blood screening using Tasso technology, included in SheMed programme plans. Tests for HbA1c, cholesterol, liver health, and kidney function at baseline, 6 months, and 12 months to support eligibility assessment and ongoing metabolic monitoring.
- SheMed Supplements Two third-party-tested supplement products available exclusively to SheMed members as rolling monthly subscriptions (£24.99/month per product): GLP-1 Daily Support & Sleep (magnesium glycinate) and Hair, Skin & Nails (hydrolysed marine collagen with vitamin C and biotin), each supplied as a 28-day pack of 56 capsules.
Quantifiable outcome
- Members can lose up to 28% of body weight
- +5 more outcomes
Companies that use SheMed
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles4 records
SheMed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
SheMed partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- eMed Healthcare UKcoreGPhC-registered pharmacy partner (registration number 9012578, Superintendent Pharmacist Yee Lai, registration 2207949) providing dispensing and medication fulfilment. Clinical, consultation, and prescribing services provided by eMed (CQC-registered provider, registration 1-1690359844). All eMed clinicians are UK-registered and licensed.
- Birmingham City Football ClubminorSheMed is a proud sponsor of Birmingham City FC. Partnership includes promotional prize draws (game ticket raffles, Christmas Giveaway, seasonal promotions) and community health initiatives.
Scale indicators7 records
Recent moves5 records
Expansion highlights6 records
SheMed competitors and assessment
Company assessmentDirect peers
- Second Nature: UK-based digital weight management programme combining lifestyle coaching with optional GLP-1 medication prescribing. Comparable subscription model and UK focus, though with a stronger non-clinical coaching orientation.
- Juniper: UK-based telehealth subscription service providing clinician-led weight loss treatment with GLP-1 medications (Wegovy/Mounjaro) targeted at women. Directly comparable on geography, business model, and target demographic.
- Voy: UK weight-loss telehealth subscription providing personalised plans with clinician support, GLP-1 medications, and app-based tracking. Direct UK competitor in the same female-inclusive D2C GLP-1 subscription category.
- Zava: UK/European online doctor and pharmacy offering weight loss treatment, sexual health, and chronic condition management via online consultation and home delivery. Comparable D2C online-clinic model serving UK consumers with subscription prescriptions.
- Numan: UK digital health platform offering subscription-based access to clinician-prescribed treatments including weight loss (GLP-1s), men's health, and hair loss. Comparable on D2C telehealth subscription model and UK geographic focus.
- Habitual: UK digital weight loss programme offering clinician-led care with GLP-1 prescribing and behavioural support. Direct competitor on subscription-based remote weight management in the UK market.
Broad incumbents
- Ro: US D2C telehealth platform with a dedicated weight loss programme (Ro Body) using GLP-1 medications, plus broader primary care and pharmacy. Comparable end-to-end digital clinic model, though US-focused and broader portfolio.
- Manual: UK D2C men's health platform that has expanded into weight loss (including GLP-1 treatments). Comparable D2C subscription telehealth model targeting UK consumers, though historically men's health-focused.
- Babylon Health: Former UK digital primary care leader (now part of eMed) and prior employer of two SheMed C-suite executives. Provides the broader digital-health platform and clinical infrastructure underpinning UK telehealth, including the eMed pharmacy/prescribing partnership SheMed relies on.
- Hims & Hers Health: US-listed D2C telehealth platform offering weight loss (GLP-1) subscriptions alongside broader wellness categories. Comparable subscription model and category mix, though US-focused and much larger scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SheMed social profiles
Digital presenceSheMed compliance and trust
Trust signalCompliance2 records
SheMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
SheMed leadership team
Management profileNumber of profiles
Profiles9 records
SheMed funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SheMed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SheMed
What does SheMed do?
SheMed is a UK women's health technology company offering a clinician-led, personalised medical weight loss programme built around GLP-1 medications (Wegovy and Mounjaro injections, plus oral Wegovy pill). The service combines at-home needle-free blood testing for metabolic screening, ongoing clinician oversight, and an all-in-one mobile app for ordering, tracking, and check-ins. Membership is delivered via recurring subscription bundles that include medication, blood tests, clinical support, and side-effect care.
Is SheMed a public or private company?
SheMed is a private company. It is classified as venture growth investor backed and is currently operating.
When was SheMed founded?
SheMed was founded in 2024. It employs 11 to 50 people.
Where is SheMed based?
SheMed is headquartered in London, United Kingdom, in the Europe region.
How does SheMed make money?
Three revenue lines are on record. Weight Loss Programme Subscription is the primary driver. The others are supplements and affiliate Commission.
Who are SheMed's main competitors?
Direct peers on record are Second Nature, Juniper, Voy, Zava, Numan and Habitual. Broad incumbents are Ro, Manual, Babylon Health and Hims & Hers Health.
Does SheMed have an API?
No public API is recorded for SheMed.
What industry is SheMed in?
SheMed's product category is Women's Telehealth Weight Management. Its primary akta.pro industry code is HLALAAAD, Prescription-Based Digital Clinics (Condition-Specific Rx Programs), with a secondary code of HLALAIAH, Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing. Its NAICS code is 6219 and its SIC code is 8000.